Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.05 +2.0%	$1.99	$1.60 ▼ $2.54	$790.64M	1.03	1.36 million shs	1.07 million shs
OCS Oculis	$18.17 +1.7%	$18.92	$10.79 ▼ $23.08	$793.34M	0.29	45,173 shs	6,005 shs
QURE uniQure	$15.20 +5.4%	$14.66	$4.45 ▼ $19.18	$832.66M	0.08	1.44 million shs	2.14 million shs
VTYX Ventyx Biosciences	$3.27 +4.5%	$2.08	$0.78 ▼ $3.39	$232.70M	0.93	1.43 million shs	884,791 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	-0.50%	-3.37%	+4.15%	+13.56%	-16.94%
OCS Oculis	-0.17%	-3.09%	-7.17%	-2.24%	+52.32%
QURE uniQure	+3.30%	-3.03%	-4.57%	+10.92%	+56.57%
VTYX Ventyx Biosciences	+3.30%	+30.42%	+23.23%	+192.52%	-2.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.6105 of 5 stars	0.0	4.0	1.6	0.0	2.5
OCS Oculis	1.9156 of 5 stars	3.5	3.0	1.5	0.0	0.6
QURE uniQure	2.5696 of 5 stars	3.5	1.0	3.3	2.5	0.6
VTYX Ventyx Biosciences	3.5092 of 5 stars	3.4	5.0	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
OCS Oculis	3.00	Buy	$35.33	95.05% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	142.46% Upside
VTYX Ventyx Biosciences	2.75	Moderate Buy	$10.00	206.28% Upside

Current Analyst Ratings Breakdown

Latest VTYX, CRON, QURE, and OCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	QURE uniQure	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/12/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/9/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
5/6/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/21/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/17/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $32.00
4/17/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.71	$0.00 per share	4,341.10	$2.90 per share	0.71
OCS Oculis	$780K	1,013.98	N/A	N/A	$1.91 per share	9.48
QURE uniQure	$27.12M	31.51	N/A	N/A	($0.14) per share	-111.41
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	15.73	68.17	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.64	N/A	N/A	N/A	-13,788.70%	-92.95%	-70.03%	8/26/2025 (Estimated)
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.75	N/A	N/A	N/A	N/A	-47.45%	-43.49%	8/14/2025 (Estimated)

Latest VTYX, CRON, QURE, and OCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRON Cronos Group	-$0.02	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	QURE uniQure	-$0.89	N/A	N/A	N/A	N/A	N/A
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/8/2025	Q1 2025	VTYX Ventyx Biosciences	-$0.48	-$0.39	+$0.09	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
OCS Oculis	N/A	4.79	4.79
QURE uniQure	1.53	11.99	11.99
VTYX Ventyx Biosciences	N/A	19.57	19.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
OCS Oculis	22.30%
QURE uniQure	78.83%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
OCS Oculis	N/A
QURE uniQure	4.79%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	357.53 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
QURE uniQure	500	54.78 million	52.15 million	Optionable
VTYX Ventyx Biosciences	30	71.16 million	60.85 million	Optionable

VTYX, CRON, QURE, and OCS Headlines

Recent News About These Companies

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - Nasdaq

July 11, 2025 | nasdaq.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 10, 2025 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)

June 24, 2025 | theglobeandmail.com

VTYX - Ventyx Biosciences Inc News - Morningstar

June 24, 2025 | morningstar.comM

VTYX - Ventyx Biosciences Inc Financials - Morningstar

June 24, 2025 | morningstar.comM

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m

June 17, 2025 | finance.yahoo.com

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives

June 17, 2025 | marketwatch.com

Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial

June 17, 2025 | msn.com

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results

June 17, 2025 | msn.com

Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data

June 17, 2025 | investing.com

Ventyx Biosciences Reports Positive Phase 2a Study Results for VTX3232 in Early-Stage Parkinson's Disease

June 17, 2025 | quiverquant.comQ

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

June 17, 2025 | globenewswire.com

Ventyx Biosciences reports annual meeting results

June 12, 2025 | investing.com

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025 | globenewswire.com

Why Ventyx Biosciences, Inc.’s (VTYX) Stock Is Down 6.88%

May 7, 2025 | aaii.comA

Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

May 4, 2025 | finance.yahoo.com

Ventyx Biosciences announces seven additional appointments to SAB

April 2, 2025 | markets.businessinsider.com

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

April 1, 2025 | globenewswire.com

Ventyx Biosciences Reports 2024 Financial Results and Progress

March 4, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Tech Stocks Poised for Explosive EPS Growth in 2025
By Gabriel Osorio-Mazilli | July 8, 2025
View 3 Tech Stocks Poised for Explosive EPS Growth in 2025
Micron Insiders Sell But Investors Should Buy, Buy, Buy
By Thomas Hughes | July 7, 2025
View Micron Insiders Sell But Investors Should Buy, Buy, Buy
Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
By Thomas Hughes | June 26, 2025
View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook
By Leo Miller | July 3, 2025
View Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook

VTYX, CRON, QURE, and OCS Company Descriptions

Cronos Group NASDAQ:CRON

$2.05 +0.04 (+1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$2.03 -0.02 (-0.98%)

As of 06:57 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Oculis NASDAQ:OCS

$18.17 +0.31 (+1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$18.00 -0.17 (-0.94%)

As of 04:04 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

uniQure NASDAQ:QURE

$15.20 +0.78 (+5.41%)

Closing price 04:00 PM Eastern

Extended Trading

$15.32 +0.12 (+0.79%)

As of 06:45 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Ventyx Biosciences NASDAQ:VTYX

$3.27 +0.14 (+4.47%)

Closing price 04:00 PM Eastern

Extended Trading

$3.20 -0.08 (-2.29%)

As of 06:31 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time